GSK Partners With SBP Group to Expand Hepatitis B Treatment
LONDON, UK – May 11, 2026 GSK plc announced an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group) through...
Breakthrough Therapy Designation
Advertisement
Innovent Secures Third NMPA Breakthrough Status for IBI363
SAN FRANCISCO and SUZHOU, China, May 10, 2026 Innovent Biologics, Inc. announced that China’s National Medical Products Administration (NMPA)...
GSK Bepirovirsen Wins FDA Priority Review Breakthrough Status
LONDON, United Kingdom, April 28, 2026 GSK has announced that its investigational antisense oligonucleotide therapy bepirovirsen has been accepted...
Ficerafusp Alfa Shows Strong Responses in HNSCC
BOSTON, Mass., Feb. 20, 2026 — New clinical findings presented at a major oncology symposium demonstrate that ficerafusp alfa...
FDA Grants Breakthrough Therapy Status to Bezuclastinib in GIST
Waltham, Massachusetts & Boulder, Colorado, January 26, 2026 — Cogent Biosciences, Inc. announced that the U.S. Food and Drug...
Advertisements
FDA Grants Breakthrough Status to Ianalumab in Sjögren’s
Basel, January 16, 2026 — Novartis announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation...
vTv Therapeutics Strengthens Balance Sheet for Phase 3
HIGH POINT, N.C., November 6, 2025 — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company developing innovative oral...
Zenocutuzumab-zbco Earns FDA Breakthrough Therapy Status for NRG1+ Cholangiocarcinoma
LEXINGTON, Mass., October 23, 2025– Partner Therapeutics, Inc. (PTx), a fully integrated biotechnology company, announced that the U.S. Food...
Daiichi Sankyo and Merck Strengthen ADC Pipeline with FDA Nod
BASKING RIDGE, N.J. and RAHWAY, N.J., September 15, 2025 – Daiichi Sankyo and Merck (known as MSD outside the...
FDA Approves J&J’s INLEXZO™, Redefining Bladder Cancer Care
September 9, 2025 – Raritan, N.J. – In a landmark regulatory milestone, Johnson & Johnson (NYSE: JNJ) announced U.S....
Advertisement
